



(12) Translation of
European patent specification

(11) NO/EP 3070090 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 9/00 (2006.01)
A61K 9/20 (2006.01)
A61K 31/519 (2006.01)
C07D 487/04 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.05.06
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.12.12
(86)	European Application Nr.	16152794.0
(86)	European Filing Date	2008.06.12
(87)	The European Application's Publication Date	2016.09.21
(30)	Priority	2007.06.13, US, 943705 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
	Designated Extension States:	AL ; BA ; MK ; RS
(62)	Divided application	EP2740731, filing date 2008.06.12
(73)	Proprietor	Incyte Holdings Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA
(72)	Inventor	LI, Hui-Yin, 176 Thompson Drive, Hockessin, DE 19707, USA RODGERS, James, D., 2 Hillside Lane, Landenberg, PA 19350, USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Postboks 7007 M, 0306 OSLO, Norge

(54)	Title	USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
(56)	References Cited:	WO-A-01/42246, WO-A-2006/096270, WO-A-2007/070514

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Andvendelse av et salt valgt fra gruppen bestående av
 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-
 cyklopentylpropannitril fosforsyre salt;
5 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-
 cyklopentylpropannitril svovelsyre salt; og
 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-
 cyklopentylpropannitril maleinsyre salt for fremstillingen av et legemiddel for
 behandling av polycytemia vera.
10
2. Anvendelse ifølge krav 1, hvor saltet er (R)-3-(4-(7H-pyrrolo[2,3-
 d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyklopentylpropannitrilfosforsyre-salt.
3. Anvendelse ifølge krav 1 eller krav 2, hvor saltet er krystallinsk.
15
4. Anvendelse ifølge krav 3, hvor det krystallinske salt er 1: 1 (R)-3-(4-(7H-
 pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyklopentylpropannitril :
 fosforsyre-salt.